Peritoneal Adhesiolysis without CC/MCC DRG Reimbursement

DRG 337 includes inpatient admissions for peritoneal adhesiolysis without a Major Complication or Comorbidity and without a Complication or Comorbidity; it covers surgical management of intra-abdominal adhesions when no higher-severity diagnoses are present. Correct classification affects Medicare inpatient prospective payment because the Diagnosis-Related Group assignment determines relative resource weights and payment levels.

DRG 337 Overview

DRG 337 covers hospital inpatient admissions for peritoneal adhesiolysis procedures without a Major Complication or Comorbidity and without a Complication or Comorbidity. This group captures surgical interventions to lyse intra-abdominal adhesions when no higher-severity comorbid conditions are present. It matters for Medicare payment because assignment to this Diagnosis-Related Group influences average resource intensity and the prospective payment amount for the admission. Accurate coding of procedures and comorbid conditions determines whether an episode is classified in DRG 337 versus a higher-severity group.

Acute surgical intervention trials: randomized or pragmatic studies comparing different intraoperative adhesiolysis techniques (such as sharp dissection versus blunt dissection, use of laparoscopic versus open approaches, or variations in energy devices) in adults undergoing peritoneal adhesiolysis for adhesive small bowel obstruction or symptomatic adhesive disease. These trials enroll patients presenting for emergent or urgent operative management and measure short-term outcomes like operative time, intraoperative complications, need for bowel resection, and length of stay. Results inform surgeons and hospital payers about procedure safety, resource utilization, and potential to reduce downstream costs by minimizing complications and reoperations.
Comparative effectiveness and prevention studies of adhesion reduction strategies: prospective cohort studies or randomized comparisons evaluating adjuncts used at the time of adhesiolysis (for example, barrier agents, minimally invasive access, or optimized irrigation protocols) to reduce recurrent adhesion formation and subsequent readmissions. These studies typically include patients who have had prior abdominal surgery and now require adhesiolysis, assessing recurrence rates of adhesive obstruction, chronic abdominal pain, and long-term need for additional operations. Findings are relevant for health systems and payers because effective adhesion prevention can decrease readmission rates, long-term morbidity, and cumulative inpatient costs associated with repeated procedures coded under this DRG.
Post-discharge outcomes and utilization studies: observational research and registry-based analyses tracking recovery trajectories, functional status, opioid use, and post-acute care needs among patients discharged after peritoneal adhesiolysis without CC/MCC. These studies focus on real-world patients across age groups and comorbidity profiles to identify predictors of prolonged recovery, early readmission, and outpatient resource consumption (e.g., home health, rehabilitation). Understanding these patterns helps providers optimize discharge planning and helps payers anticipate post-discharge expenditures and design value-based care pathways to reduce avoidable readmissions linked to this DRG.

Acute surgical intervention trials: randomized or pragmatic studies comparing different intraoperative adhesiolysis techniques (such as sharp dissection versus blunt dissection, use of laparoscopic versus open approaches, or variations in energy devices) in adults undergoing peritoneal adhesiolysis for adhesive small bowel obstruction or symptomatic adhesive disease. These trials enroll patients presenting for emergent or urgent operative management and measure short-term outcomes like operative time, intraoperative complications, need for bowel resection, and length of stay. Results inform surgeons and hospital payers about procedure safety, resource utilization, and potential to reduce downstream costs by minimizing complications and reoperations.
Comparative effectiveness and prevention studies of adhesion reduction strategies: prospective cohort studies or randomized comparisons evaluating adjuncts used at the time of adhesiolysis (for example, barrier agents, minimally invasive access, or optimized irrigation protocols) to reduce recurrent adhesion formation and subsequent readmissions. These studies typically include patients who have had prior abdominal surgery and now require adhesiolysis, assessing recurrence rates of adhesive obstruction, chronic abdominal pain, and long-term need for additional operations. Findings are relevant for health systems and payers because effective adhesion prevention can decrease readmission rates, long-term morbidity, and cumulative inpatient costs associated with repeated procedures coded under this DRG.
Post-discharge outcomes and utilization studies: observational research and registry-based analyses tracking recovery trajectories, functional status, opioid use, and post-acute care needs among patients discharged after peritoneal adhesiolysis without CC/MCC. These studies focus on real-world patients across age groups and comorbidity profiles to identify predictors of prolonged recovery, early readmission, and outpatient resource consumption (e.g., home health, rehabilitation). Understanding these patterns helps providers optimize discharge planning and helps payers anticipate post-discharge expenditures and design value-based care pathways to reduce avoidable readmissions linked to this DRG.

OpenPayer

Summary & Overview

Peritoneal Adhesiolysis without CC/MCC: Inpatient Reimbursement Overview

DRG 337 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes